Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Nervous System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Nervous System Neoplasm

Cancer Family

Nervous System Neoplasm

CI-CAN-00000038Explore in graph →

Non-malignant1,523 active trials9 approved drugs210 evidence items

NCIt: C3268
MeSH: D009423

Overview
Statistics
Survival
Genomics48
Variants & evidence210
Drugs47
Trials5870
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (168)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 29, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 168 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Residential Radon Concentration and the Risk of Malignant Brain and Central Nervous System Cancer in US Postmenopausal Women.
Carson Mowrer, Eric A Whitsel, Jason M Collins et al. · Neuroepidemiology · Sep 1, 2026 · PMID 42678905 · candidate dictionary pubmed
MGMT gene silencing and benefit from temozolomide in glioblastoma.
· N Engl J Med · 2005 · PMID 15758010 · validated civic_curation pubmed
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
· N Engl J Med · 2023 · PMID 37272516 · validated civic_curation pubmed
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
· Nat Med · 2024 · PMID 37978284 · validated civic_curation pubmed
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors.
· Cancer Cell · 2009 · PMID 19962671 · validated civic_curation pubmed
Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR.
· Nat Genet · 2014 · PMID 24316981 · validated civic_curation pubmed
The molecular landscape of ETMR at diagnosis and relapse.
· Nature · 2019 · PMID 31802000 · validated civic_curation pubmed

Showing 1–25 of 168 publications

← Previous
1
2
…
7
Next →

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

· Cancer Cell · 2014 · PMID 25517749 · validated civic_curation pubmed

Selumetinib in Children with Inoperable Plexiform Neurofibromas.

· N Engl J Med · 2020 · PMID 32187457 · validated civic_curation pubmed

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma.

· J Clin Oncol · 2023 · PMID 36375115 · validated civic_curation pubmed

ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.

· J Clin Oncol · 2024 · PMID 38335473 · validated civic_curation pubmed

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

· N Engl J Med · 2016 · PMID 28029918 · validated civic_curation pubmed

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

· Cancer Discov · 2017 · PMID 28183697 · validated civic_curation pubmed

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

· Acta Neuropathol · 2016 · PMID 27157931 · validated civic_curation pubmed

IDH1 and IDH2 mutations in gliomas.

· N Engl J Med · 2009 · PMID 19228619 · validated civic_curation pubmed

Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

· Nat Genet · 2013 · PMID 23817572 · validated civic_curation pubmed

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.

· Lancet Oncol · 2017 · PMID 28545823 · validated civic_curation pubmed

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

· N Engl J Med · 2000 · PMID 11070098 · validated civic_curation pubmed

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

· J Clin Oncol · 2009 · PMID 19901104 · validated civic_curation pubmed

TERT promoter mutations in primary and secondary glioblastomas.

· Acta Neuropathol · 2013 · PMID 23955565 · validated civic_curation pubmed

Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.

· Cancer Cell · 2014 · PMID 24651015 · validated civic_curation pubmed

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

· N Engl J Med · 2005 · PMID 16282176 · validated civic_curation pubmed

Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study.

· Mod Pathol · 2000 · PMID 11144931 · validated civic_curation pubmed

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

· Lancet Oncol · 2013 · PMID 23598171 · validated civic_curation pubmed

LRP1B deletion is associated with poor outcome for glioblastoma patients.

· J Neurol Sci · 2015 · PMID 26428308 · validated civic_curation pubmed